Jazz Pharmaceuticals plc
JAZZ- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001232524
In the last 90 days, Jazz Pharmaceuticals plc insiders filed 0 open-market purchases and 6 sales; 648 institutions reported holding it in 13F filings for Q2 2026, worth $15.5B in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Jazz Pharmaceuticals plc insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 6 filings
- 4 insiders, $24.4M in total
- Insiders trading
- 4
- Net value
- −$24.4M
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Jazz Pharmaceuticals plc, current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Patil Neena M | EVP & Chief Legal Officer | 47,671 | Sep 14, 2026 | 7 |
| Gala Renee D | President & CEO | 143,394 | Sep 10, 2026 | 7 |
| Henderson Mary Elizabeth | SVP, Technical Operations | 23,815 | Sep 10, 2026 | 7 |
| Smith Mark Douglas | Director | 9,579 | Sep 2, 2026 | 3 |
| Riedel Norbert G | Director | 6,923 | Sep 2, 2026 | 3 |
| Love Ted W | Director | 2,389 | Sep 2, 2026 | 3 |
| Hamill Laura | Director | 6,832 | Sep 2, 2026 | 2 |
| Cook Jennifer E. | Director | 10,736 | Sep 2, 2026 | 2 |
| Enright Patrick G | Director | 21,278 | Sep 2, 2026 | 3 |
| McSharry Heather Ann | Director | 18,199 | Sep 2, 2026 | 4 |
| Kennedy Patrick | Director | 6,452 | Sep 2, 2026 | 2 |
| Winningham Rick E | Director | 9,466 | Sep 2, 2026 | 4 |
| Cozadd Bruce C | Director | 351,875 | Sep 2, 2026 | 13 |
| Iannone Robert | EVP, Global Head of R&D & CMO | 65,686 | Aug 31, 2026 | 6 |
| Pearce Samantha | EVP, Chief Commercial Officer | 47,131 | Aug 7, 2026 | 6 |
| Mulligan Seamus | Director | 1,184,633 | Aug 7, 2026 | 2 |
| Johnson Philip L | EVP & Chief Financial Officer | 56,431 | Jul 2, 2026 | 3 |
| Carr Patricia | SVP, Chief Accounting Officer | 6,512 | Mar 9, 2026 | 5 |
| O'Keefe Kenneth W | Director | 25,811 | Dec 4, 2025 | 1 |
| ORiordan Anne | Director | 16,500 | Aug 11, 2025 | 0 |
| Sohn Catherine A. | Director | 14,868 | Aug 15, 2023 | 0 |
| Gray Peter | Director | 16,068 | Aug 15, 2023 | 0 |
| Sablich Kim | EVP, GM of U.S. | 28,478 | Jun 7, 2023 | 0 |
| Swisher Daniel N JR | President and COO | 55,014 | Mar 7, 2023 | 0 |
| Larkin Finbar | SVP, Technical Operations | 21,779 | Mar 7, 2023 | 0 |
| Tovey Christopher J. | EVP, COO & Managing Director E | 14,663 | Jul 7, 2022 | 0 |
| Berns Paul L | Director | 8,290 | Aug 9, 2021 | 0 |
| Schnee Elmar | Director | 8,270 | Aug 9, 2021 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 10, 2026 (view filing)4:33 PM ET | Sep 8 | 2 days | Gala Renee DPresident & CEO | SSale | −2.00K | $243.03 | −$486.1K | −1.4%143.4K after | 10b5-1 |
| Sep 14, 2026 (view filing)6:38 PM ET | Sep 10 | 4 days | Patil Neena MEVP & Chief Legal Officer | SSale | −1.20K | $240.94 | −$289.1K | −2.5%47.7K after | 10b5-1 |